Serotonergic drugs and valvular heart disease

Bibliography

• Weiger WA. Serotonergic modulation of behaviour: a phylogenetic overview. Biol Rev Camb Philos Soc 1997;72(1):61-95
   PubMed Web of Science ®Google Scholar
• Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71(4):533-54
   PubMed Web of Science ®Google Scholar
• Nichols DE, Nichols CD. Serotonin receptors. Chem Rev 2008;108(5):1614-41
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337(9):581-8
   PubMed Web of Science ®Google Scholar
• Connolly HM, McGoon MD. Obesity drugs and the heart. Curr Probl Cardiol 1999;24:745-92
   PubMed Web of Science ®Google Scholar
• Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002;144(6):1065-73
   PubMed Web of Science ®Google Scholar
• Loke YK, Derry S, Pritchard-Copley A. Appetite suppressants and valvular heart disease - a systematic review. BMC Clin Pharmacol 2002;2:6
   PubMedGoogle Scholar
• Gardin JM, Weissman NJ, Leung C, et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001;286:2011-4
   PubMed Web of Science ®Google Scholar
• Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation [see comments]. N Engl J Med 1998;339:719-24
   PubMed Web of Science ®Google Scholar
• Fleming RM, Boyd LB. The longitudinal effects of fenfluramine-phentermine use. Angiology 2007;58(3):353-9
   PubMed Web of Science ®Google Scholar
• Weissman NJ. Appetite suppressants and valvular heart disease. Am J Med Sci 2001;321:285-91
   PubMed Web of Science ®Google Scholar
• Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008;6(1):34
   PubMed Web of Science ®Google Scholar
• Baumann MH, Ayestas MA, Dersch CM, et al. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 2000;36:102-13
   PubMed Web of Science ®Google Scholar
• Rothman RB, Clark RD, Partilla JS, Baumann MH. (+)-fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J Pharmacol Exp Ther 2003;305(3):1191-9
   PubMed Web of Science ®Google Scholar
• Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 1986;83:674-8
   PubMed Web of Science ®Google Scholar
• Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 1988;335:254-6
   PubMed Web of Science ®Google Scholar
• Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther 2006;318(2):604-10
   PubMed Web of Science ®Google Scholar
• Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356(1):6-9
   PubMed Web of Science ®Google Scholar
• Pinder RM, Brogden RN, Sawyer PR, et al. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975;10:241-323
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann M. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002;95(1):73-88
   PubMed Web of Science ®Google Scholar
• Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters [review]. Biochim Biophys Acta 1993;1144:249-63
   PubMed Web of Science ®Google Scholar
• Garattini S, Mennini T, Bendotti C, et al. Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system. Appetite 1986;7(Suppl):15-38
   PubMed Web of Science ®Google Scholar
• Gundlah C, Martin KF, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 1997;283:581-91
   PubMed Web of Science ®Google Scholar
• Tao R, Fray A, Aspley S, et al. Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. Eur J Pharmacol 2002;445(1-2):69-81
   PubMed Web of Science ®Google Scholar
• Caccia S, Conforti I, Duchier J, Garattini S. Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days. Eur J Clin Pharmacol 1985;29:221-4
   PubMed Web of Science ®Google Scholar
• Marchant NC, Breen MA, Wallace D, et al. Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man. Xenobiotica 1992;22(11):1251-66
   PubMed Web of Science ®Google Scholar
• Rothman RB, Partilla JS, Baumann MH, et al. Neurochemical neutralization of methamphetamine with high affinity non-selective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse 2000;35:222-7
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41
   PubMed Web of Science ®Google Scholar
• Pettersson E. Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro. Eur J Pharmacol 1995;282:131-5
   PubMed Web of Science ®Google Scholar
• Cozzi NV, Frescas S, Marona-Lewicka D, et al. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol Biochem Behav 1998;59:709-15
   PubMed Web of Science ®Google Scholar
• Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation 1999;100:869-75
   PubMedGoogle Scholar
• Garattini S. Biological actions of drugs affecting serotonin and eating. Obes Res 1995;3(Suppl 4):463S-70S
   PubMedGoogle Scholar
• Vickers SP, Clifton PG, Dourish CT, Tecott LH. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 1999;143:309-14
   PubMed Web of Science ®Google Scholar
• Vickers SP, Benwell KR, Porter RH, et al. Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats . Br J Pharmacol 2000;130(6):1305-14
   PubMed Web of Science ®Google Scholar
• Silverstone T. Appetite suppressants. A review. Drugs 1992;43:820-36
   PubMed Web of Science ®Google Scholar
• Tecott LH, Abdallah L. Mouse genetic approaches to feeding regulation: serotonin 5-HT2C receptor mutant mice. CNS spectrums 2003;8(8):584-8
   PubMedGoogle Scholar
• Xu Y, Jones JE, Kohno D, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008;60(4):582-9
   PubMed Web of Science ®Google Scholar
• Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41
   PubMed Web of Science ®Google Scholar
• Launay JM, Herve P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8(10):1129-35
   PubMed Web of Science ®Google Scholar
• Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation 1999;99:156-61
   PubMed Web of Science ®Google Scholar
• Martin F, Artigas F. Simultaneous effects of p-chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J Neurochem 1992;59:1138-44
   PubMed Web of Science ®Google Scholar
• Rothman RB, Redmon JB, Raatz SK, et al. Chronic treatment with the phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 2000;85:913-5
   PubMed Web of Science ®Google Scholar
• Buczko W, De Gaetano G, Garattini S. Effect of some anorectic agents on the uptake and release of 5-hydroxytryptamine by blood platelets of rats. J Pharm Pharmacol 1975;27:366-8
   PubMed Web of Science ®Google Scholar
• Picotti GB, Carruba MO, Zambotti F, Mantegazza P. Effects of mazindol and d-fenfluramine of 5-hydroxytryptamine uptake, storage and metabolism in blood platelets. Eur J Pharmacol 1977;42(3):217-24
   PubMed Web of Science ®Google Scholar
• Schuldiner S, Steiner-Mordoch S, Yelin R, et al. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 1993;44:1227-31
   PubMed Web of Science ®Google Scholar
• Johnson GJ, Leis LA, Dunlop PC, Weir EK. The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost 2003;1(12):2663-8
   PubMed Web of Science ®Google Scholar
• Zolkowska D, Baumann MH, Rothman RB. Chronic fenfluramine administration increases plasma serotonin (5-HT) to non-toxic levels. J Pharmacol Exp Ther 2007;324(2):791-7
   PubMed Web of Science ®Google Scholar
• Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit 2001;23(2):139-47
   PubMed Web of Science ®Google Scholar
• Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-5
   PubMedGoogle Scholar
• Gustafsson BI, Tommeras K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005;111(12):1517-22
   PubMed Web of Science ®Google Scholar
• Droogmans S, Franken PR, Garbar C, et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 2007;28(17):2156-62
   PubMed Web of Science ®Google Scholar
• Donnelly KB. Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases. Toxicol Pathol 2008;36(2):204-17
   PubMed Web of Science ®Google Scholar
• Smith BM, Thomsen WJ, Grottick AJ. The potential use of selective 5-HT2C agonists in treating obesity. Expert Opin Investig Drugs 2006;15(3):257-66
   PubMed Web of Science ®Google Scholar
• Kema IP, de Vries EG, Schellings AM, et al. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Clin Chem 1992;38(4):534-40
   PubMed Web of Science ®Google Scholar
• Kema IP, Meijer WG, Meiborg G, et al. Profiling of tryptophan-related plasma indoles in patients with carcinoid tumors by automated, on-line, solid-phase extraction and HPLC with fluorescence detection. Clin Chem 2001;47(10):1811-20
   PubMed Web of Science ®Google Scholar
• Meijer WG, Kema IP, Volmer M, et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000;46(10):1588-96
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Raffestin B, Launay JM, et al. Effect of Dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. Am J Respir Crit Care Med 1998;157:1111-9
   PubMed Web of Science ®Google Scholar
• Artigas F, Sarrias MJ, Martinez E, et al. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology (Berl) 1989;99:328-32
   PubMed Web of Science ®Google Scholar
• Celada P, Dolera M, Alvarez E, Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. J Affect Disord 1992;25(4):243-9
   PubMed Web of Science ®Google Scholar
• MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000;131(2):161-8
   PubMed Web of Science ®Google Scholar
• Bana DS, MacNeal PS, LeCompte PM, et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974;88:640-55
   PubMed Web of Science ®Google Scholar
• Bredberg U, Eyjolfsdottir GS, Paalzow L, et al. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol 1986;30:75-7
   PubMed Web of Science ®Google Scholar
• Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 1996;5:235-7
   PubMed Web of Science ®Google Scholar
• Mast ST, Gersing KR, Anstrom KJ, et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001;87:989-93
   PubMed Web of Science ®Google Scholar
• Whigham LD, Dhurandhar NV, Rahko PS, Atkinson RL. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. Int J Obesity 2007;31(5):850-7
   PubMed Web of Science ®Google Scholar
• Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002;144(3):508-15
   PubMed Web of Science ®Google Scholar
• Ishida M, Otani K, Kaneko S, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995;10(3):143-6
   PubMed Web of Science ®Google Scholar
• Otani K, Mihara K, Yasui N, et al. Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 1997;21(1):239-44
   PubMed Web of Science ®Google Scholar
• Hoyer D, Clarke DE, Fozard JR, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994;46:157-203
   PubMed Web of Science ®Google Scholar
• Baumann MH, Rutter JJ, Auerbach SB. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology 1993;32:1381-6
   PubMed Web of Science ®Google Scholar
• Baumann MH, Ayestas MA, Dersch CM, Rothman RB. 1-(m-Chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 2001;24:492-501
   PubMed Web of Science ®Google Scholar
• Porter RH, Benwell KR, Lamb H, et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 1999;128:13-20
   PubMed Web of Science ®Google Scholar
• Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003;63(6):1223-9
   PubMed Web of Science ®Google Scholar
• Setola V, Roth BL. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen-phen’. Expert Opin Drug Metab Toxicol 2005;1(3):377-87
   PubMedGoogle Scholar
• Lopez-Ilasaca M. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 1998;56:269-77
   PubMed Web of Science ®Google Scholar
• Hafizi S, Taylor PM, Chester AH, et al. Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents. J Heart Valve Dis 2000;9(3):454-8
   PubMed Web of Science ®Google Scholar
• Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006;29(2):80-6
   PubMed Web of Science ®Google Scholar
• Droogmans S, Cosyns B, D'Haenen H, et al. Possible association between 3,4-Methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 2007;100(9):442-5
   PubMed Web of Science ®Google Scholar
• Devereux RB. Appetite suppressants and valvular heart disease. N Engl J Med 1998;339:765-7
   PubMed Web of Science ®Google Scholar
• Maher TJ, Ulus IH, Wurtman RJ. Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines. Lancet 1999;353:38
   PubMedGoogle Scholar
• Alexander M, Rothman RB, Baumann MH, et al. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse 2005;56(2):94-9
   PubMed Web of Science ®Google Scholar
• Karlsen SN, Spigset O, Slordal L. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. Basic Clin Pharmacol Toxicol 2008;102(1):15-24
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006;101(3):348-61
   PubMed Web of Science ®Google Scholar